News round-up for 16-20 October by DDW Digital Content Editor Diana Spencer.
To celebrate DDW’s first Turning Science into Business Summit on ‘Cancer research opportunities and advances’, the news round-up this week highlights the latest developments in oncology drug discovery.
The top stories:
DDW Cancer Research Summit: Strategies to get to market faster
The DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances’ will feature experts and thought leaders in cancer research, precision medicine and immunotherapy.
Orphan designated precision drug approved in US for NSCLC
The US Food and Drug Administration (FDA) has approved orphan drug encorafenib (Braftovi) with binimetinib (Mektovi) for adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation.
CAR T therapy successfully treats solid tumours in China
CARsgen has published evidence of over seven years of disease-free survival in advanced hepatocellular carcinoma (HCC) following treatment with its CAR-GPC3 T cell therapy.
Researchers reverse prostate cancer drug resistance
Prostate cancer’s resistance to treatment can be reversed in some patients by stopping hijacked white blood cells from being ‘pulled into’ tumours, according to new research published in Nature.
Paediatric models for preclinical testing of oncology drugs
The US Food and Drug Administration’s (FDA) Research to Accelerate Cures and Equity (RACE) for Children Act now requires all oncology drugs to be tested for paediatric indications ahead of approval.
